These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

344 related articles for article (PubMed ID: 17928873)

  • 1. Generation of a high-titer packaging cell line for the production of retroviral vectors in suspension and serum-free media.
    Ghani K; Cottin S; Kamen A; Caruso M
    Gene Ther; 2007 Dec; 14(24):1705-11. PubMed ID: 17928873
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Retroviral vector production using suspension-adapted 293GPG cells in a 3L acoustic filter-based perfusion bioreactor.
    Ghani K; Garnier A; Coelho H; Transfiguracion J; Trudel P; Kamen A
    Biotechnol Bioeng; 2006 Nov; 95(4):653-60. PubMed ID: 16947907
    [TBL] [Abstract][Full Text] [Related]  

  • 3. A novel human suspension culture packaging cell line for production of high-titre retroviral vectors.
    Chan LM; Coutelle C; Themis M
    Gene Ther; 2001 May; 8(9):697-703. PubMed ID: 11406764
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Suspension packaging cell lines for the simplified generation of T-cell receptor encoding retrovirus vector particles.
    Reuss S; Biese P; Cosset FL; Takeuchi Y; Uckert W
    Gene Ther; 2007 Apr; 14(7):595-603. PubMed ID: 17235289
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Effects of culture parameters on the production of retroviral vectors by a human packaging cell line.
    McTaggart S; Al-Rubeai M
    Biotechnol Prog; 2000; 16(5):859-65. PubMed ID: 11027182
    [TBL] [Abstract][Full Text] [Related]  

  • 6. A retroviral packaging cell line for pseudotype vectors based on glioma-infiltrating progenitor cells.
    Fischer YH; Miletic H; Giroglou T; Litwak S; Stenzel W; Neumann H; von Laer D
    J Gene Med; 2007 May; 9(5):335-44. PubMed ID: 17474071
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Production of retroviral vectors for gene therapy with the human packaging cell line FLYRD18.
    Gerin PA; Searle PF; Al-Rubeai M
    Biotechnol Prog; 1999; 15(5):941-8. PubMed ID: 10514266
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Development and characterization of a cell line for large-scale, serum-free production of recombinant adeno-associated viral vectors.
    Farson D; Harding TC; Tao L; Liu J; Powell S; Vimal V; Yendluri S; Koprivnikar K; Ho K; Twitty C; Husak P; Lin A; Snyder RO; Donahue BA
    J Gene Med; 2004 Dec; 6(12):1369-81. PubMed ID: 15538729
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Enhancement of retroviral production from packaging cell lines expressing the human immunodeficiency type 1 VPU gene.
    Kobinger GP; Mouland AJ; Lalonde JP; Forget J; Cohen EA
    Gene Ther; 1997 Aug; 4(8):868-74. PubMed ID: 9338017
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Generation of a packaging cell line for prolonged large-scale production of high-titer HIV-1-based lentiviral vector.
    Ni Y; Sun S; Oparaocha I; Humeau L; Davis B; Cohen R; Binder G; Chang YN; Slepushkin V; Dropulic B
    J Gene Med; 2005 Jun; 7(6):818-34. PubMed ID: 15693055
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Development of a suspension packaging cell line for production of high titre, serum-resistant murine leukemia virus vectors.
    Pizzato M; Merten OW; Blair ED; Takeuchi Y
    Gene Ther; 2001 May; 8(10):737-45. PubMed ID: 11420637
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Construction of a retroviral vector production system with the minimum possibility of a homologous recombination.
    Yu SS; Han E; Hong Y; Lee JT; Kim S; Kim S
    Gene Ther; 2003 Apr; 10(8):706-11. PubMed ID: 12692599
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Comparison of different bioreactor systems for the production of high titer retroviral vectors.
    Merten OW; Cruz PE; Rochette C; Geny-Fiamma C; Bouquet C; Gonçalves D; Danos O; Carrondo MJ
    Biotechnol Prog; 2001; 17(2):326-35. PubMed ID: 11312711
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Construction and use of a safe and efficient amphotropic packaging cell line.
    Markowitz D; Goff S; Bank A
    Virology; 1988 Dec; 167(2):400-6. PubMed ID: 2462307
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Safe and efficient ecotropic and amphotropic packaging lines for use in gene transfer experiments.
    Markowitz DG; Goff SP; Bank A
    Trans Assoc Am Physicians; 1988; 101():212-8. PubMed ID: 3077729
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Generation of high-titer retroviral vectors following receptor-mediated, adenovirus-augmented transfection.
    von Rüden T; Stingl L; Cotten M; Wagner E; Zatloukal K
    Biotechniques; 1995 Mar; 18(3):484-9. PubMed ID: 7779400
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Large-scale manufacturing of safe and efficient retrovirus packaging lines for use in immunotherapy protocols.
    Farson D; McGuinness R; Dull T; Limoli K; Lazar R; Jalali S; Reddy S; Pennathur-Das R; Broad D; Finer M
    J Gene Med; 1999; 1(3):195-209. PubMed ID: 10738568
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Generation of stable retrovirus packaging cell lines after transduction with herpes simplex virus hybrid amplicon vectors.
    Sena-Esteves M; Hampl JA; Camp SM; Breakefield XO
    J Gene Med; 2002; 4(3):229-39. PubMed ID: 12112640
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Construction of new retroviral producer cells from adenoviral and retroviral vectors.
    Lin X
    Gene Ther; 1998 Sep; 5(9):1251-8. PubMed ID: 9930327
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Development of a scalable process for high-yield lentiviral vector production by transient transfection of HEK293 suspension cultures.
    Ansorge S; Lanthier S; Transfiguracion J; Durocher Y; Henry O; Kamen A
    J Gene Med; 2009 Oct; 11(10):868-76. PubMed ID: 19618482
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 18.